RAAP Cautions States Against Implementing 'Most Favored Nation' Drug Pricing Strategies The Rare Access Action Project (RAAP) has issued a cautionary policy paper warning states against adopting 'Most Favored Nation' drug pricing models, citing risks for patient access.

RAAP Cautions States Against Implementing 'Most Favored Nation' Drug Pricing Strategies #USA #Washington #Most_Favored_Nation #Rare_Access_Action_Project #Prescription_Drug_Affordability

RAAP Urges Virginia Legislators to Thoroughly Study PDAB Bill Before Action The Rare Access Action Project calls on Virginia lawmakers to fully evaluate the PDAB bill before making hasty decisions affecting patient care and drug costs.

RAAP Urges Virginia Legislators to Thoroughly Study PDAB Bill Before Action #United_States #Virginia #PDAB #Rare_Access_Action_Project

Virginia Legislators Urged to Rethink Prescription Drug Affordability Board Measures Virginia lawmakers are being cautioned against the proposed Prescription Drug Affordability Boards, which may harm patients rather than help. Experts weigh in on the controversy and suggest alternatives.

Virginia Legislators Urged to Rethink Prescription Drug Affordability Board Measures #USA #Virginia #Rare_Access_Action_Project #Prescription_Drug_Affordability #Virginia_Politics

The Risks of Alternative Funding Programs for Rare Disease Patients' Health This article explores the dangers posed by Alternative Funding Programs (AFPs), which often compel patients to use unsafe therapies not approved by the FDA.

The Risks of Alternative Funding Programs for Rare Disease Patients' Health #United_States #Washington #Gilead_Sciences #Rare_Access_Action_Project #FDA_warnings

The Critical Need for Innovation in Rare Disease Treatments: Moving Beyond Cost Analyses The debate around funding for rare disease therapies must shift from cost to innovation, ensuring access for vulnerable patients. We explore the implications of recent changes.

The Critical Need for Innovation in Rare Disease Treatments: Moving Beyond Cost Analyses #USA #Innovation #Washington #Orphan_Drug_Act #Rare_Access_Action_Project